Logo

Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) in 1L RCC Based in P-III CheckMate-214 study

Share this

Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) in 1L RCC Based in P-III CheckMate-214 study

Shots:
  • CHMP recommendation is based on the results of P-III CheckMate-214 study assessing Opdivo 3 mg/kg (q3w @four doses- q2w) + Yervoy 1 mg/kg vs sunitinib (50 mg qd @four weeks) in ~900 patients with 1L intermediate- and poor-risk advanced renal cell carcinoma (RCC)
  • P-III CheckMate-214 study results: increase in OS; 37% reduction in death of patients; DRR (41.6% vs 26.5%); no new safety signals observed
  • Opdivo is a PD-1 immune checkpoint inhibitor involved in fighting against cancer cells and is approved in >65 countries including the US- EU- Japan- China
Ref: Bristol-Myers Squibb | Image: New Drug Approvals

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions